$2.90
0.34% today
Nasdaq, Nov 04, 09:15 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Target price 2024 - Analyst rating & recommendation

Editas Medicine, Inc. Classifications & Recommendation:

Buy
53%
Hold
47%

Editas Medicine, Inc. Price Target

Target Price $11.27
Price $2.91
Potential
Number of Estimates 15
15 Analysts have issued a price target Editas Medicine, Inc. 2025 . The average Editas Medicine, Inc. target price is $11.27. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 10 Analysts recommend Editas Medicine, Inc. to buy, 9 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Editas Medicine, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Editas Medicine, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 78.12 26.28
296.35% 66.36%
EBITDA Margin -208.81% -969.64%
81.26% 364.37%
Net Margin -213.14% -919.88%
84.12% 331.58%

17 Analysts have issued a sales forecast Editas Medicine, Inc. 2024 . The average Editas Medicine, Inc. sales estimate is

$26.3m
Unlock
. This is
60.79% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$72.4m 8.01%
Unlock
, the lowest is
$1.6m 97.61%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $78.1m 296.35%
2024
$26.3m 66.36%
Unlock
2025
$19.1m 27.41%
Unlock
2026
$50.6m 164.97%
Unlock
2027
$154m 205.61%
Unlock
2028
$256m 65.77%
Unlock

5 Analysts have issued an Editas Medicine, Inc. EBITDA forecast 2024. The average Editas Medicine, Inc. EBITDA estimate is

$-255m
Unlock
. This is
22.98% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-207m 0.05%
Unlock
, the lowest is
$-292m 40.92%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-163m 25.72%
2024
$-255m 56.22%
Unlock
2025
$-260m 2.11%
Unlock
2026
$-248m 4.56%
Unlock

EBITDA Margin

2023 -208.81% 81.26%
2024
-969.64% 364.37%
Unlock
2025
-1,363.96% 40.67%
Unlock
2026
-491.29% 63.98%
Unlock

7 Editas Medicine, Inc. Analysts have issued a net profit forecast 2024. The average Editas Medicine, Inc. net profit estimate is

$-242m
Unlock
. This is
24.28% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-204m 5.09%
Unlock
, the lowest is
$-279m 43.65%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-167m 37.07%
2024
$-242m 45.19%
Unlock
2025
$-226m 6.73%
Unlock
2026
$-220m 2.52%
Unlock
2027
$-109m 50.28%
Unlock
2028
$-64.8m 40.68%
Unlock

Net Margin

2023 -213.14% 84.12%
2024
-919.88% 331.58%
Unlock
2025
-1,182.01% 28.50%
Unlock
2026
-434.84% 63.21%
Unlock
2027
-70.75% 83.73%
Unlock
2028
-25.32% 64.21%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.02 -2.93
37.07% 45.05%
P/E negative
EV/Sales negative

7 Analysts have issued a Editas Medicine, Inc. forecast for earnings per share. The average Editas Medicine, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.93
Unlock
. This is
24.15% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.48 5.08%
Unlock
, the lowest is
$-3.39 43.64%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.02 37.07%
2024
$-2.93 45.05%
Unlock
2025
$-2.74 6.48%
Unlock
2026
$-2.67 2.55%
Unlock
2027
$-1.33 50.19%
Unlock
2028
$-0.79 40.60%
Unlock

P/E ratio

Current -1.23 41.71%
2024
-0.99 19.51%
Unlock
2025
-1.06 7.07%
Unlock
2026
-1.09 2.83%
Unlock
2027
-2.19 100.92%
Unlock
2028
-3.70 68.95%
Unlock

Based on analysts' sales estimates for 2024, the Editas Medicine, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-0.02
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -0.01 100.17%
2024
-0.02 52.00%
Unlock
2025
-0.02 38.16%
Unlock
2026
-0.01 62.38%
Unlock
2027
0.00 67.09%
Unlock
2028
0.00 38.46%
Unlock

P/S ratio

Current 3.58 86.46%
2024
9.13 155.05%
Unlock
2025
12.58 37.76%
Unlock
2026
4.75 62.26%
Unlock
2027
1.55 67.28%
Unlock
2028
0.94 39.68%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today